RIPK3 Orchestrates Scar‐Associated Macrophage Dysfunction to Drive Pulmonary Fibrosis
Advanced Science · 2026
DOI: 10.1002/advs.202519404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Tao Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Idiopathic Pulmonary Fibrosis, Macrophages, Cicatrix. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant tissue remodeling and immune dysregulation. While receptor‐interacting protein kinase 3 (RIPK3) is canonically recognized as a central executioner of necroptosis, its non‐necroptotic functions in fibrosis remain unclear. Here, we identify a distinct, necroptosis‐independent immunometabolic function of RIPK3 in regulating pulmonary fibrosis. Significant upregulation of RIPK3 was found in IPF patients and mice and was particularly enriched in macrophages. Subsequently, macrophage‐specific RIPK3 knockout mice were established, which demonstrated resistance to bleomycin‐induced fibrosis. Single‐cell RNA sequencing further revealed that RIPK3 exerts its pro‐fibrotic effects by controlling the functional state of a specific subset of scar‐associated macrophages (SAMs). In vitro differentiation and functional analysis of SAMs from bone marrow‐derived monocytes confirmed Spp1 , Arg1 , and Cx3cr1 as signature markers. Mechanistically, RIPK3 deficiency in SAMs inhibited the TGF‐β‐driven conversion of arginine to polyamines via the AKT‐mTOR pathway, thereby suppressing polyamine accumulation and its pro‐fibrotic effects. The translational potential of this finding was validated, as lung‐specific Ripk3 knockdown also attenuated lung fibrosis. Our findings extend RIPK3 biology beyond its classical role in cell death, highlighting RIPK3 as a key metabolic regulator of the fibrotic niche and suggesting that targeting this immunometabolic axis represents a promising therapeutic strategy for IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- School of Pharmacy, University of Chinese Academy of Sciences, Beijing, China.
- The Institute of Clinical Pharmacology, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Anhui Medical Unive…
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
Förderung
- Chinese Academy of Sciences
- National Natural Science Foundation of China
Zitieren
APA
Yang, T., Li, X., Lei, S., Li, Q., Zhang, Y., Hui, Z., Ren, J., Yang, X., Yang, X., Feng, C., Xu, Y., Zhao, D., & Tang, W. (2026). RIPK3 Orchestrates Scar‐Associated Macrophage Dysfunction to Drive Pulmonary Fibrosis. Advanced Science. https://doi.org/10.1002/advs.202519404
Vancouver
Yang T, Li X, Lei S, Li Q, Zhang Y, Hui Z, et al. RIPK3 Orchestrates Scar‐Associated Macrophage Dysfunction to Drive Pulmonary Fibrosis. Advanced Science. 2026. doi:10.1002/advs.202519404
BibTeX
@article{Yang2026,
author = {Yang, Tao and Li, Xiao and Lei, Shuyue and Li, Qingqing and Zhang, Yi and Hui, Zhizhen and Ren, Jinjin and Yang, Xuelian and Yang, Xiaoqian and Feng, Chunlan and Xu, Yousheng and Zhao, Dongxin and Tang, Wei},
title = {RIPK3 Orchestrates Scar‐Associated Macrophage Dysfunction to Drive Pulmonary Fibrosis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202519404}
}
EUVIMED